RLAYHealthcare · BiotechnologyThe 13 Wall Street analysts covering Relay Therapeutics, Inc. hold a median 12-month price target of $28 — +51.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 24 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Relay Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (95): The shares have been drifting up relative to others.
Revisions (36): Analysts have, on balance, been cutting their forecasts.
Size (26): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RLAY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +51.3% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $28 → $29 |
| 14 Aug 2026 | JP Morgan | Maintains | Overweight | $28 → $31 |
| 10 Aug 2026 | Citizens | Maintains | Market Outperform | — |
| 10 Aug 2026 | Citizens | Maintains | Market Outperform | $21 → $26 |
| 7 Aug 2026 | Barclays | Maintains | Overweight | — |
| 7 Aug 2026 | Barclays | Maintains | Overweight | $27 → $30 |
| 21 July 2026 | Goldman Sachs | Maintains | Buy | $22 → $31 |
| 21 July 2026 | Goldman Sachs | Maintains | Buy | — |
| 16 July 2026 | Canaccord Genuity | Initiates | Buy | $29 |
| 16 July 2026 | Canaccord Genuity | Initiates | Buy | — |
| 8 July 2026 | JP Morgan | Initiates | Overweight | — |
| 26 May 2026 | Guggenheim | Maintains | Buy | — |
| 26 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 May 2026 | Barclays | Maintains | Overweight | — |
| 20 May 2026 | Citizens | Maintains | Market Outperform | — |
| 19 May 2026 | Raymond James | Maintains | Strong Buy | — |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 28 Apr 2026 | Goldman Sachs | Maintains | Buy | — |
| 28 Apr 2026 | Oppenheimer | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RLAY appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Relay Therapeutics, Inc. returned +168.9% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 2% of US stocks
Cheaper than 22% of US stocks
Cheaper than 86% of US stocks
Higher than 6% of US stocks
Higher than 11% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 25% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Relay Therapeutics, Inc. has a market value of $4.0B and an enterprise value of $3.1B.
Revenue in the twelve months to 30 June 2026: $10.3M. The latest quarter shrank 48.3% year on year.
Net income over the same four quarters: −$286.0M, a −2763.6% net margin.
Diluted earnings per share, trailing twelve months: $−1.57.
Free cash flow in the twelve months to 30 June 2026: −$212.2M.
Trailing P/E: −11.3×; forward P/E: −11.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Relay Therapeutics, Inc. employs 202 people — $51K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Relay Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
On CNBC’s “Closing Bell Overtime,” Goldman Sachs lead U.S. biotech analyst Salveen Richter discussed biotech innovations in China. The headline says large biopharma companies are looking at China assets.
Why it matters — The discussion concerns biopharma activity and innovation in China, but the excerpt does not mention Relay Therapeutics specifically.
Relay Therapeutics, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference. A transcript of the presentation has been published on Seeking Alpha.
Why it matters — A Relay Therapeutics watcher would care because the conference presentation offers insight into the company's corporate and pipeline updates as relayed to investors in a public forum.
Relay Therapeutics presented prepared remarks at the Wells Fargo 21st Annual Healthcare Conference, with the remarks transcript published by Seeking Alpha. The presentation covered the company's prepared remarks at the investor conference.
Why it matters — A RLAY watcher would care because the conference presentation offers insight into how the company communicates its business and pipeline to the investment community.
Relay Therapeutics' CFO sold 17,717 shares in a transaction valued at approximately $350,000. The sale reduced the executive's direct equity position by 11%.
Why it matters — A watcher of Relay Therapeutics would care because this insider sale reveals a notable reduction in the CFO's direct equity stake in the company.
Relay Therapeutics announced that its management will participate in two upcoming investor conference fireside chats in September. The company described itself as a clinical-stage precision medicine developer focused on cancer and genetic disease therapies.
Why it matters — This indicates management's ongoing engagement with the investment community during September, giving RLAY watchers visibility into the company's presence at investor events.
The 13 Wall Street analysts covering Relay Therapeutics, Inc. have a median 12-month price target of $28, with estimates ranging from $20 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Relay Therapeutics, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Relay Therapeutics, Inc. 71 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, Relay Therapeutics, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +51.3% from the last close, and Ticker Nerd's factor model ranks Relay Therapeutics, Inc. 71 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Relay Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLAY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $32 over the next 12 months.
Relay Therapeutics, Inc. returned +168.9% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Relay Therapeutics Inc. is a clinical-stage precision medicines company focused on discovering and developing small-molecule therapies for oncology and genetic disease.
The most recent item we track (CNBC Television, 6 Oct 2026): "Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter". On CNBC’s “Closing Bell Overtime,” Goldman Sachs lead U.S. biotech analyst Salveen Richter discussed biotech innovations in China. The headline says large biopharma companies are looking at China assets.
Relay Therapeutics Inc. is a clinical-stage precision medicines company focused on discovering and developing small-molecule therapies for oncology and genetic disease. The company uses its proprietary Dynamo platform to combine computational modeling, structural biology, medicinal chemistry, and experimental biology in order to address protein targets that have been difficult to drug with conventional methods. Its current pipeline centers on targeted cancer programs, including candidates for genetically defined tumors, as well as selected genetic disease applications. Relay Therapeutics Inc. operates in the biopharmaceutical sector with a strong emphasis on precision oncology, where it aims to design more selective therapies for molecularly characterized diseases. Based in Cambridge, Massachusetts, the company works at the intersection of drug discovery technology and clinical development, making it a notable participant in the small-molecule precision medicine market.
CEO Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS · 202 employees · United States · https://www.relaytx.com
